Small-molecule inhibitors that target LIF/LIFR, such as EC359 and EC330, were used to treat ovarian cancer (OCa), breast cancer, and endometrial cancer (ECa), which inhibited tumor development in OCa cells, ECa cells, and breast cancer MCF7 cells [111,112,113,114,116]. This evidence concerns the gene LIFR and breast cancer.